Skip to search formSkip to main contentSkip to account menu

Ticagrelor

Known as: (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-D)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (2)

AZD6140Brilique

Broader (2)

AdenosinePurinergic P2Y Receptor Antagonists
Ticagrelor 60 MG Oral Tablet [Brilinta]Ticagrelor 90 MG Oral Tabletanalogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Low-dose Ticagrelor in Patients With High Ischemic Risk and Prior Myocardial Infarction: a Multicenter Prospective Real-World Observational Study.
Prolonged dual antiplatelet therapy (DAPT) after 12 months in patients with prior myocardial infarction is attractive to reduce… 
2016
2016
Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine
BackgroundTicagrelor inhibits the equilibrative-nucleoside-transporter-1 and thereby, adenosine cell re-uptake. Ticagrelor limits… 
2016
2016
Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry
Abstract In randomized clinical trials, ticagrelor has been substituted in roughly one-third of the patients during follow-up. To… 
Review
2015
Review
2015
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
2014
2014
Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
Review
2013
Review
2013
Genetic variation of platelet function and pharmacology: An update of current knowledge
Summary Platelets are critically involved in atherosclerosis and acute thrombosis. The platelet phenotype shows a wide… 
Review
2013
Review
2013
Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications.
2011
2011
The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome
The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome 
Review
2011
Review
2011
Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Ticagrelor
Landmark clinical trials established the benefit of the thienopyridine clopidogrel, an irreversibly binding inhibitor of the… 
2010
2010
Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA…
BackgroundRecently we have demonstrated a dose-dependent improvement of endothelial function after administration of a single… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)